Psyence BioMed Welcomes U.S. Administration’s Latest Action to Accelerate Ibogaine Development

RegulatoryIbogainePositive

AI Analysis

Summary

Psyence BioMed announced that the U.S. Administration has taken action to accelerate ibogaine development. The specific nature of the regulatory action and its implications for the company's program are not detailed in the article.

Outcome Details

U.S. Administration action to accelerate ibogaine development

Importance:6/10

Sentiment:

0.70

ibogaineregulatorydrug developmentacceleration

Related Companies

$PBM

Read the original article

Published by yahoo_finance on August 18, 2026 9:23 PM

Read Original